Rapid onset of efficacy of rasagiline in early Parkinson's disease

Sandro Zambito Marsala, Roberta Vitaliani, Daniele Volpe, Francesca Capozzoli, Luciana Baroni, Enrico Belgrado, Carlo Borsato, Manuela Gioulis, Corrado Marchini, Angelo Antonini

Research output: Contribution to journalArticlepeer-review


Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson's disease (PD). This naturalistic single-blind study was aimed at evaluating the rapidity of onset effect of rasagiline on motor symptoms in a cohort of early relatively elderly PD patients. 102 outpatients (55 males, median age 71 years) have been selected: 26 were PD therapy-naive and 76 received rasagiline as add-on therapy. The third section of the Unified Parkinson's Disease Rating Scale (UPDRSIII) and the Hoehn-Yahr (HY) scale were assessed at baseline and after 1 and 4 weeks thereafter. The mean UPDRS III total score (-6.7 at week 1 and -8.9 at week 4) and single items, as well as mean HY score (-0.40 at week 1 and -0.67 at week 4), significantly decreased from baseline (p <0.001). Improvements were significant in both therapy-naive and add-on therapy patients: the mean decreases from baseline to week 4 in UPDRSIII and HY score were -8.8 and -0.46, and -9.0 and -0.74, respectively, in the two subgroups. The mean decrease from baseline in UPDRSIII and HY score did not significantly differ in patients aged > or ≤71 years. Rasagiline had a rapid therapeutic effect from the first week of therapy, which further improved at 4 weeks. The rapid onset of action and the absence of a dose titration are important issues in the management of the PD patient.

Original languageEnglish
Pages (from-to)2007-2013
Number of pages7
JournalNeurological Sciences
Issue number11
Publication statusPublished - Nov 2013


  • Early improvement
  • Motor symptoms
  • Rasagiline

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology


Dive into the research topics of 'Rapid onset of efficacy of rasagiline in early Parkinson's disease'. Together they form a unique fingerprint.

Cite this